Apremilast Regulates the Teff/Treg Balance to Ameliorate Uveitis via PI3K/AKT/FoxO1 Signaling Pathway
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apremilast Regulates the Teff/Treg Balance to Ameliorate Uveitis via PI3K/AKT/FoxO1 Signaling Pathway
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-11-17
DOI
10.3389/fimmu.2020.581673
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Review of FoxO1-Regulated Metabolic Diseases and Related Drug Discoveries
- (2020) Shiming Peng et al. Cells
- Emerging role of PTEN loss in evasion of the immune response to tumours
- (2020) Thiago Vidotto et al. BRITISH JOURNAL OF CANCER
- Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
- (2020) Ningni Jiang et al. MOLECULAR BIOLOGY REPORTS
- Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours
- (2020) Fei Xu et al. Cell and Bioscience
- IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis
- (2019) Tue W. Kragstrup et al. Therapeutic Advances in Musculoskeletal Disease
- Polyphenols in the treatment of autoimmune diseases
- (2019) Haroon Khan et al. AUTOIMMUNITY REVIEWS
- Baicalin ameliorates neuroinflammation-induced depressive-like behavior through inhibition of toll-like receptor 4 expression via the PI3K/AKT/FoxO1 pathway
- (2019) Li-Ting Guo et al. Journal of Neuroinflammation
- Uveitis: Autoimmunity… and beyond
- (2019) Pierre-Jean Bertrand et al. AUTOIMMUNITY REVIEWS
- cAMP/PKA signaling compartmentalization in cardiomyocytes: Lessons from FRET-based biosensors
- (2019) Alessandra Ghigo et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- The Bu Shen Yi Sui Formula Promotes Axonal Regeneration via Regulating the Neurotrophic Factor BDNF/TrkB and the Downstream PI3K/Akt Signaling Pathway
- (2019) Qi Zheng et al. Frontiers in Pharmacology
- Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet’s disease
- (2019) Giuseppe Lopalco et al. ANNALS OF THE RHEUMATIC DISEASES
- CXCL16/CXCR6 axis promotes bleomycin-induced fibrotic process in MRC-5 cells via the PI3K/AKT/FOXO3a pathway
- (2019) Zhenzhen Ma et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome
- (2019) Gülen Hatemi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resolution of uveitis
- (2019) Gerhild Wildner et al. Seminars in Immunopathology
- Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice
- (2019) Peter H. Schafer et al. Drugs in research & development
- Mucosal Immunity and the FOXO1 Transcription Factors
- (2019) Dana T. Graves et al. Frontiers in Immunology
- Teriflunomide suppresses T helper cells and dendritic cells to alleviate experimental autoimmune uveitis
- (2019) Zhuang Li et al. BIOCHEMICAL PHARMACOLOGY
- Baicalin modulates the Treg/Teff balance to alleviate uveitis by activating the aryl hydrocarbon receptor
- (2018) Wenjie Zhu et al. BIOCHEMICAL PHARMACOLOGY
- Phosphodiesterase 4 inhibitors
- (2018) Rema Zebda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- PI3K/Akt Cooperates with Oncogenic Notch by Inducing Nitric Oxide-Dependent Inflammation
- (2018) Santiago Nahuel Villegas et al. Cell Reports
- Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4+Foxp3+ Regulatory T Cells Differentiation
- (2018) Weiqian Chen et al. Frontiers in Immunology
- Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses
- (2017) Michael Abrouk et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders
- (2017) Patrizia Fasching et al. MOLECULES
- Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies
- (2016) Kevin Kelly et al. CLINICAL CANCER RESEARCH
- AKT isoforms modulate Th1‐like Treg generation and function in human autoimmune disease
- (2016) Alexandra Kitz et al. EMBO REPORTS
- A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus
- (2016) Madhvi Menon et al. IMMUNITY
- Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity
- (2016) Chong T. Luo et al. NATURE
- Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
- (2015) Melinda Gooderham et al. BIODRUGS
- New treatment paradigms in psoriatic arthritis
- (2015) Maria L. Acosta Felquer et al. CURRENT OPINION IN RHEUMATOLOGY
- Imbalance Between Th17 Cells and Regulatory T Cells During Monophasic Experimental Autoimmune Uveitis
- (2015) Lian Zhang et al. INFLAMMATION
- Foxo1 Is a T Cell–Intrinsic Inhibitor of the RORγt-Th17 Program
- (2015) Alexandra Lainé et al. JOURNAL OF IMMUNOLOGY
- Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
- (2015) Miguel Perez-Aso et al. ARTHRITIS RESEARCH & THERAPY
- Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- FoxO1 Gene Confers Genetic Predisposition to Acute Anterior Uveitis With Ankylosing Spondylitis
- (2014) H. Yu et al. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
- Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway
- (2014) Rashika Joshi et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Phosphodiesterase 4-targeted treatments for autoimmune diseases
- (2013) Neal Kumar et al. BMC Medicine
- Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
- (2012) Kim Papp et al. LANCET
- Phosphatidylinositol 3-Kinase Signaling in Thymocytes: The Need for Stringent Control
- (2010) E. Fayard et al. Science Signaling
- Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
- (2010) Fiona E McCann et al. ARTHRITIS RESEARCH & THERAPY
- Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
- (2009) PH Schafer et al. BRITISH JOURNAL OF PHARMACOLOGY
- Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor
- (2009) Hon-Wah Man et al. JOURNAL OF MEDICINAL CHEMISTRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started